Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) SVP Paula Green sold 291 shares of the stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $41.68, for a total value of $12,128.88. Following the completion of the transaction, the senior vice president now directly owns 130,621 shares in the company, valued at $5,444,283.28. The trade was a 0.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Paula Green also recently made the following trade(s):
- On Thursday, March 6th, Paula Green sold 918 shares of Twist Bioscience stock. The shares were sold at an average price of $40.91, for a total value of $37,555.38.
- On Monday, February 3rd, Paula Green sold 1,259 shares of Twist Bioscience stock. The stock was sold at an average price of $49.35, for a total transaction of $62,131.65.
- On Friday, January 3rd, Paula Green sold 160 shares of Twist Bioscience stock. The shares were sold at an average price of $45.59, for a total transaction of $7,294.40.
Twist Bioscience Trading Up 4.8 %
NASDAQ:TWST opened at $44.94 on Tuesday. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a twelve month low of $27.41 and a twelve month high of $60.90. The company has a market cap of $2.68 billion, a P/E ratio of -13.30 and a beta of 2.15. The business has a 50 day moving average price of $45.42 and a two-hundred day moving average price of $45.31.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business had revenue of $88.70 million during the quarter, compared to analysts' expectations of $86.96 million. During the same quarter in the prior year, the company posted ($0.75) earnings per share. The firm's revenue was up 24.1% on a year-over-year basis. As a group, analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.
Analyst Ratings Changes
Several brokerages have recently issued reports on TWST. JPMorgan Chase & Co. boosted their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a report on Tuesday, February 4th. Wolfe Research started coverage on Twist Bioscience in a research note on Friday, December 13th. They issued an "outperform" rating and a $60.00 target price for the company. Barclays set a $58.00 price target on Twist Bioscience and gave the stock an "overweight" rating in a research report on Monday, February 3rd. TD Cowen reiterated a "buy" rating and issued a $58.00 price objective on shares of Twist Bioscience in a research report on Tuesday, November 26th. Finally, Robert W. Baird raised their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a report on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $54.40.
Check Out Our Latest Analysis on Twist Bioscience
Institutional Trading of Twist Bioscience
Several institutional investors and hedge funds have recently bought and sold shares of TWST. Wilmington Savings Fund Society FSB bought a new position in Twist Bioscience in the third quarter valued at approximately $34,000. Van ECK Associates Corp boosted its holdings in shares of Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after buying an additional 267 shares during the last quarter. Banque Transatlantique SA bought a new position in shares of Twist Bioscience in the fourth quarter valued at $43,000. GF Fund Management CO. LTD. acquired a new position in Twist Bioscience during the fourth quarter worth $58,000. Finally, US Bancorp DE raised its position in Twist Bioscience by 72.0% during the fourth quarter. US Bancorp DE now owns 1,436 shares of the company's stock worth $67,000 after acquiring an additional 601 shares in the last quarter.
Twist Bioscience Company Profile
(
Get Free Report)
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
